Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin plus metformin versus acarbose plus metformin in type 2 diabetes
ChiCTR1900022751Phase 4Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Apr 2019
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin, acarbose and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Glycated hemoglobin. Started Apr 2019; status: recruiting.
02
Drugs
dapagliflozinacarbosemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900022751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022751.